Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$37.23
-4.3%
$33.19
$29.31
$61.38
$4.45B0.591.54 million shs1.37 million shs
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$68.49
$68.47
$21.65
$73.02
$4.62B0.452.07 million shs74 shs
Perrigo Company plc stock logo
PRGO
Perrigo
$26.95
-0.7%
$26.82
$23.14
$30.93
$3.71B0.451.42 million shs614,445 shs
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$33.57
-6.8%
$34.64
$16.01
$44.34
$3.73B0.99919,429 shs858,756 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
0.00%+0.59%+13.75%-5.70%-34.44%
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.00%0.00%0.00%0.00%0.00%
Perrigo Company plc stock logo
PRGO
Perrigo
0.00%-2.07%+2.34%+6.33%-2.78%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
0.00%+2.57%-9.10%+16.40%+79.14%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
4.1061 of 5 stars
4.51.00.04.62.50.80.0
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
4.62 of 5 stars
2.12.04.23.53.41.72.5
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
3.3621 of 5 stars
3.45.00.00.03.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.93
Moderate Buy$70.9290.50% Upside
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.00
N/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
2.25
Hold$33.0022.45% Upside
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
2.80
Moderate Buy$54.2861.68% Upside

Current Analyst Ratings Breakdown

Latest CYTK, GBT, PRGO, and ZLAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$73.00 ➝ $75.00
6/9/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$71.00 ➝ $53.00
5/29/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$103.00 ➝ $84.00
5/14/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
5/13/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/8/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.00
5/7/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$82.00 ➝ $80.00
5/7/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$86.00 ➝ $80.00
5/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$47.00 ➝ $41.00
5/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
4/24/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Overweight$55.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$19.22M231.36N/AN/A($1.15) per share-32.37
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$194.75M23.73N/AN/A$3.05 per share22.46
Perrigo Company plc stock logo
PRGO
Perrigo
$4.37B0.85$5.05 per share5.34$31.66 per share0.85
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$398.99M9.35N/AN/A$7.68 per share4.37
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$589.53M-$5.29N/AN/AN/A-3,201.47%N/A-43.75%8/6/2025 (Estimated)
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
-$303.09M-$5.01N/AN/AN/A-137.30%-170.37%-39.24%N/A
Perrigo Company plc stock logo
PRGO
Perrigo
-$171.80M-$1.31N/A8.81N/A-4.16%8.93%3.87%8/1/2025 (Estimated)
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$257.10M-$2.49N/AN/AN/A-60.26%-33.35%-23.28%8/7/2025 (Estimated)

Latest CYTK, GBT, PRGO, and ZLAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.32N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$0.42N/AN/AN/A$125.66 millionN/A
8/1/2025Q2 2025
Perrigo Company plc stock logo
PRGO
Perrigo
$0.59N/AN/AN/A$1.08 billionN/A
5/8/2025Q1 2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$0.50-$0.45+$0.05-$0.45$118.40 million$106.49 million
5/7/2025Q1 2025
Perrigo Company plc stock logo
PRGO
Perrigo
$0.56$0.60+$0.04-$0.05$1.09 billion$1.04 billion
5/6/2025Q1 2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
$1.164.30%N/AN/A 23 Years
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/AN/AN/AN/AN/A

Latest CYTK, GBT, PRGO, and ZLAB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2025
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.294.55%5/30/20255/30/20256/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
5.99
5.99
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
4.92
6.88
6.17
Perrigo Company plc stock logo
PRGO
Perrigo
0.82
2.36
1.28
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/A
3.26
3.09

Institutional Ownership

CompanyInstitutional Ownership
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/A
Perrigo Company plc stock logo
PRGO
Perrigo
95.91%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
41.65%

Insider Ownership

CompanyInsider Ownership
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.70%
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
4.90%
Perrigo Company plc stock logo
PRGO
Perrigo
0.70%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
4.96%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250119.43 million116.20 millionOptionable
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
45767.48 million64.17 millionOptionable
Perrigo Company plc stock logo
PRGO
Perrigo
8,379137.48 million136.52 millionOptionable
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
1,869111.08 million105.57 millionOptionable

Recent News About These Companies

Zai Lab (NASDAQ:ZLAB) Shares Gap Down - Here's Why
Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$37.23 -1.66 (-4.27%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$37.21 -0.02 (-0.06%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Global Blood Therapeutics stock logo

Global Blood Therapeutics NASDAQ:GBT

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Perrigo stock logo

Perrigo NYSE:PRGO

$26.95 -0.20 (-0.74%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$26.97 +0.02 (+0.06%)
As of 07/18/2025 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Zai Lab stock logo

Zai Lab NASDAQ:ZLAB

$33.57 -2.44 (-6.78%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$34.01 +0.44 (+1.30%)
As of 07/18/2025 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.